Many patients who achieved clear skin with tapinarof treatment maintained low disease activity after a treatment-free interval.

StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note issued to investors on Tuesday morning. The brokerage issued a sell rating on the ...

Long-term nemolizumab use reduces itch, disease severity, and steroid dependence in patients with prurigo nodularis in a ...

Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...

Researchers confirmed that black-legged ticks (Ixodes scapularis) can trigger alpha-gal syndrome in humans. A 10-year ...

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

Equities researchers at StockNews.com assumed coverage on shares of Cara Therapeutics (NASDAQ:CARA – Get Free Report) in a ...

Mirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) ...

Phase 3 trial results show roflumilast cream 0.05% to be a safe and effective treatment for children with atopic dermatitis.

Joya Griffin, DVM, DACVD, discusses available treatment options for patients with pruritus, plus factors to consider when ...

Joya Griffin, DVM, DACVD, reminds Fetch Charlotte 2025 attendees to maintain a strong foundation when it comes to diagnosing ...